Clinical Trial Update: Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating cannabidiol as an adjunct to standard treatment for early psychosis, comparing CBD to placebo; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psychotic Disorders
• Schizophrenia

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: University of California, San Diego | Conditions: Early Psychosis | Phase 3 | Status: RECRUITING